Twenty-one brokerages currently cover Bristol Myers Squibb, assigning one sell rating, thirteen holds and seven buys. The average one-year price target across firms stands at $56.86. Recent reviews include a reaffirmed hold (C–) from Weiss Ratings on October 14, a maintained hold with a $53 objective by HSBC on December 10, and an upgraded strong-buy from Wall Street Zen on November 8. Morgan Stanley kept its underweight stance on December 12 but raised its objective from $36 to $37, while DBS Bank elevated the company to a moderate-buy on October 2.

Institutional ownership accounts for 76.41% of shares outstanding. In Q2, Trifecta Capital Advisors and Darwin Wealth Management each initiated stakes valued at $25,000. REAP Financial Group boosted its position by 202.8% to 639 shares, worth $30,000. In Q3, Harbor Capital Advisors increased holdings by 107.2% to 605 shares ($27,000 value) and KERR Financial Planning established a new $35,000 position.

For the quarter ended October 30, the company reported EPS of $1.63, beating consensus by $0.11, on revenue of $12.22 billion versus estimates of $11.75 billion. This represents a 2.8% year-over-year revenue increase. Return on equity reached 76.5% and net margin was 12.6%. Management set full-year 2025 EPS guidance between 6.40 and 6.60, while the consensus estimate sits at 6.74.

The board declared a quarterly dividend of $0.63 per share, payable February 2 to holders of record January 2. This marks a $0.01 increase over the prior payout, translating to a $2.52 annualized distribution and a yield of approximately 4.6%. The dividend payout ratio stands at 85.1%.